drugset / Trial / NCT05683496
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
RandomizedSequentialQuadruple-blindTreatment
Summary
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
Timeline
- Start
- 2023-02-14
- Primary completion
- 2025-05-26
- Completion
- 2025-05-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lonigutamab | Monoclonal antibody | — | Subcutaneous |